Amgen (AMGN) PT Raised to $430 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $434.03 +1.86%
Rating Summary:
18 Buy, 20 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Rating Summary:
18 Buy, 20 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Join SI Premium – FREE
RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $400.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Freedom Broker Upgrades JPMorgan (JPM) to Buy, 'Greater Upside Potential'
- Amgen (AMGN) PT Lowered to $430 at Wells Fargo
- Dexterra Group Inc. (DXT:CN) (HZNOF) PT Raised to Cdn$15.50 at Scotiabank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
